Actively Recruiting
Phase II Study Comparing Hypofractionated Versus Standard Radiation Therapy with Chemotherapy and Durvalumab in Stage III Non-Small Cell Lung Cancer
Led by University of Kansas Medical Center · Updated on 2023-12-07
50
Participants Needed
6
Research Sites
56 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a treatment approach for patients with stage IIIA or IIIB non-small cell lung cancer NSCLC. This Phase II trial compares a shorter, higher-dose radiation therapy schedule called hypofractionated intensity-modulated radiation therapy IMRT combined with chemotherapy and followed by immunotherapy durvalumab against the standard radiation schedule combined with the same chemotherapy and immunotherapy. The goal is to see if the hypofractionated method improves control of the cancer in the chest area at 18 months by 10%. This study is sponsored by the University of Kansas Medical Center.
CONDITIONS
Brief Title
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
Research Team
K
KUCC Navigation
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
